​Fat Bubble Popped: Lilly Shares Dive On Disappointing Weight-Loss Drug Sales – Tyler Durden

Fat Bubble Popped: Lilly Shares Dive On Disappointing Weight-Loss Drug Sales Shares of Eli Lilly & Co tumbled in premarket trading after third-quarter sales of its blockbuster weight-loss drug fell short of Wall Street’s expectations, with the company citing ‘inventory issues’ as the reason. In reality, it seems Lilly channeled stuffed GLP1s to cash in on the anti-obesity drug craze, only to discover demand fizzled in the quarter—likely because these drugs are expensive and insurance coverage is limited. Lilly reported third-quarter revenue from all products of about $11.4 billion, +20% yoy, yet missed the Bloomberg Consensus of $12.18. Notably, the drug Mounjaro generated $3.11 billion in revenue, while…  — Continue at ZeroHedge News : Read More